For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Performance & Growth Hormone · Comparison

Hexarelin vs PEG-MGF

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

HexarelinPEG-MGF
CategoryPerformance & Growth HormonePerformance & Growth Hormone
Also known asExamorelin, EP 23905, MF-6003PEGylated Mechano Growth Factor, Polyethylene Glycol-MGF, Long-acting MGF
EvidencePreclinical onlyPreclinical only
Dosing range50mcg–200mcg mcg, 1–3x daily (cycling recommended to prevent desensitization)100mcg–400mcg mcg, 2x weekly (Monday/Thursday or similar split)
AdministrationSubcutaneous injection, Intramuscular injectionSubcutaneous injection (preferred for systemic distribution), Intramuscular injection
Key side effectsCortisol elevation, Prolactin elevation, Water retention, Increased appetiteHypoglycemia (less pronounced than IGF-1 DES, more than native MGF due to systemic distribution), Generalized fatigue on injection days, PEG accumulation concern with very high doses over long periods (theoretical — not established at research doses), Localized injection site swelling
Cited sources1 reference2 references

Key differences

  • Administration: Hexarelin — Subcutaneous injection, Intramuscular injection; PEG-MGF — Subcutaneous injection (preferred for systemic distribution), Intramuscular injection.
  • Frequency: Hexarelin is typically 1–3x daily (cycling recommended to prevent desensitization); PEG-MGF is 2x weekly (Monday/Thursday or similar split).
  • Research depth: this profile cites 1 source for Hexarelin vs 2 for PEG-MGF.

How each works

Hexarelin

Hexarelin produces dose-dependent GH release significantly greater than GHRP-6 or Ipamorelin. It also has direct cardioprotective effects via CD36 receptor binding, independent of GH — making it unique among GHRPs. Studies show protection from ischemic cardiac injury and myocardial fibrosis reduction in animal models. Desensitization occurs with chronic continuous use.

PEG-MGF

PEGylation is a validated pharmaceutical strategy for extending peptide half-life (used in Pegasys/interferon, Somavert/pegvisomant, and others). The PEG chain shields the MGF peptide from proteolytic degradation and slows renal clearance. Research in rodent models confirms PEG-MGF preserves the biological activity of native MGF (satellite cell activation, muscle repair) with extended duration. Unlike native MGF which requires precise post-workout injection timing, PEG-MGF can be injected on a scheduled basis and still achieves systemic muscle-wide satellite cell effects.

Read the full Hexarelin profileRead the full PEG-MGF profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.